Patient with inoperable pheochromocytoma

J 2015

Patient with inoperable pheochromocytoma

BRANČÍKOVÁ, Dagmar, Zdeněk MECHL, Zdeněk ADAM, Eva JANDÁKOVÁ, Zdeněk PAVLOVSKÝ et. al.

Basic information

Original name

Patient with inoperable pheochromocytoma

Authors

BRANČÍKOVÁ, Dagmar (203 Czech Republic, guarantor, belonging to the institution), Zdeněk MECHL (203 Czech Republic), Zdeněk ADAM (203 Czech Republic, belonging to the institution), Eva JANDÁKOVÁ (203 Czech Republic, belonging to the institution), Zdeněk PAVLOVSKÝ (203 Czech Republic, belonging to the institution), Vlastimil VÁLEK (203 Czech Republic, belonging to the institution) and Tomáš ANDRAŠINA (703 Slovakia, belonging to the institution)

Edition

Current Oncology, Toronto, Multimed INC. 2015, 1198-0052

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Canada

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.829

RIV identification code

RIV/00216224:14110/15:00083405

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3747/co.22.2324

UT WoS

000356976100010

Keywords in English

Pheochromocytoma; chemoembolization; lanreotide

Abstract

V originále

Malignant pheochromocytoma is a tumour with a very low incidence that occurs sporadically or in the presence of multiple endocrine neoplasia. We present the case of a woman with a sporadic occurrence of pheochromocytoma diagnosed in the phase of multiple dissemination in the abdominal cavity and overexpressing adrenaline, noradrenaline, and dopamine. Local transarterial chemoembolization and systemic treatment with lanreotide resulted in a very good response, a decrease in the production of catecholamines for 12 months and a partial decrease for another 8 months, with stabilization of disease determined by imaging. Systemic treatment with tegafur resulted in disease stabilization lasting 50 months, after which the drug was discontinued because of adverse effects. Maintenance therapy with lanreotide continues, and no disease progression has been observed for 4 months. The treatment algorithm for such patients is multidisciplinary and must always take into account the current scope of the disease, intercurrence, and the general condition of the patient.

Citovat

BRANČÍKOVÁ, Dagmar, Zdeněk MECHL, Zdeněk ADAM, Eva JANDÁKOVÁ, Zdeněk PAVLOVSKÝ, Vlastimil VÁLEK and Tomáš ANDRAŠINA. Patient with inoperable pheochromocytoma. Current Oncology. Toronto: Multimed INC., 2015, vol. 22, No 3, p. "E216"-"E219", 4 pp. ISSN 1198-0052. Available from: https://dx.doi.org/10.3747/co.22.2324.

@article{1306351,
   author = {Brančíková, Dagmar and Mechl, Zdeněk and Adam, Zdeněk and Jandáková, Eva and Pavlovský, Zdeněk and Válek, Vlastimil and Andrašina, Tomáš},
   article_location = {Toronto},
   article_number = {3},
   doi = {http://dx.doi.org/10.3747/co.22.2324},
   keywords = {Pheochromocytoma; chemoembolization; lanreotide},
   language = {eng},
   issn = {1198-0052},
   journal = {Current Oncology},
   title = {Patient with inoperable pheochromocytoma},
   volume = {22},
   year = {2015}
}

TY  - JOUR
ID  - 1306351
AU  - Brančíková, Dagmar - Mechl, Zdeněk - Adam, Zdeněk - Jandáková, Eva - Pavlovský, Zdeněk - Válek, Vlastimil - Andrašina, Tomáš
PY  - 2015
TI  - Patient with inoperable pheochromocytoma
JF  - Current Oncology
VL  - 22
IS  - 3
SP  - "E216"-"E219"
EP  - "E216"-"E219"
PB  - Multimed INC.
SN  - 11980052
KW  - Pheochromocytoma
KW  - chemoembolization
KW  - lanreotide
N2  - Malignant pheochromocytoma is a tumour with a very low incidence that occurs sporadically or in the presence of multiple endocrine neoplasia. We present the case of a woman with a sporadic occurrence of pheochromocytoma diagnosed in the phase of multiple dissemination in the abdominal cavity and overexpressing adrenaline, noradrenaline, and dopamine. Local transarterial chemoembolization and systemic treatment with lanreotide resulted in a very good response, a decrease in the production of catecholamines for 12 months and a partial decrease for another 8 months, with stabilization of disease determined by imaging. Systemic treatment with tegafur resulted in disease stabilization lasting 50 months, after which the drug was discontinued because of adverse effects. Maintenance therapy with lanreotide continues, and no disease progression has been observed for 4 months. The treatment algorithm for such patients is multidisciplinary and must always take into account the current scope of the disease, intercurrence, and the general condition of the patient.
ER  -

BRANČÍKOVÁ, Dagmar, Zdeněk MECHL, Zdeněk ADAM, Eva JANDÁKOVÁ, Zdeněk PAVLOVSKÝ, Vlastimil VÁLEK and Tomáš ANDRAŠINA. Patient with inoperable pheochromocytoma. \textit{Current Oncology}. Toronto: Multimed INC., 2015, vol.~22, No~3, p.~''E216''-''E219'', 4 pp. ISSN~1198-0052. Available from: https://dx.doi.org/10.3747/co.22.2324.

Detailed Information on Publication Record